Details der Publikation - Randomized, double blind, safety, efficacy Doravirine/Islatravir in Treatment naïve

Randomized, double blind, safety, efficacy Doravirine/Islatravir in Treatment naïve : A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants - Randomized, double blind, safety, efficacy Doravirine/Islatravir in Tx naïve

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: HIV-1 infection and naïve to antiretroviral therapy MedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-12-2019, Last updated: 2023-06-29

ICTRP ID:	EUCTR2019-000590-23-FR MK-8591A-020 2019-000590-23-ES

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG005788242

Internformat


LEADER	01000caa a22002652 4500
001	CTG005788242
003	DE-627
005	20230629100634.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG005788242
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2019-000590-23-FR
035			\|a (UBBS_Klinische_Studien_WHO)MK-8591A-020
035			\|a (UBBS_Klinische_Studien_WHO)2019-000590-23-ES
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Randomized, double blind, safety, efficacy Doravirine/Islatravir in Treatment naïve \|b A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants - Randomized, double blind, safety, efficacy Doravirine/Islatravir in Tx naïve
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-12-2019, Last updated: 2023-06-29
650		4	\|a Medical Condition: HIV-1 infection and naïve to antiretroviral therapy MedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000590-23 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände